Drug Trial News

RSS

Italy develops vaccine candidate that neutralizes SARS-CoV-2 in mice

As the world grapples with the coronavirus disease (COVID-19), scientists race to develop treatments and vaccines to combat the viral infection. Though many ongoing trials show promise in fighting the novel coronavirus, Italian researchers claim they have developed a vaccine that can neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in animal cells.

10 May 2020

NIH clinical trial evaluates antiviral plus anti-inflammatory drug for COVID-19

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019 (COVID-19) has begun.

8 May 2020

HMGB1 protein may play a key role in pulmonary inflammation, tissue damage in severe COVID-19 cases

In severe cases of COVID-19, a massive release of the endogenous protein HMGB1 in the lungs may contribute to pulmonary inflammation and tissue damage, according to a review article published today in the scientific journal Molecular Medicine.

8 May 2020

Excluding children from COVID-19 clinical trials may limit their treatment options

A new viewpoint article from Harvard Medical School, published in the journal JAMA Pediatrics, discusses the hesitancy to include children in coronavirus disease 2019 (COVID-19) clinical trials, potentially diminishing their therapeutic options in the long run.

7 May 2020

Combination therapy trial to understand the biology, spread, treatment of COVID-19

The HonorHealth Research Institute and HonorHealth announced today the successful enrollment on a novel combination of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection.

6 May 2020

Study provides evidence for safety and efficacy of chloroquine in COVID-19

After a pilot study (Huang et al.Journal of Molecular Cell Biology, in press), having proved the safety and effectiveness of the drug to reduce the viral RNA to undetectable levels in 10 COVID-19 patients, the researchers began this current study, published on the preprint server medRxiv.

5 May 2020

Hydroxychloroquine shown to slow recovery for COVID-19 patients

As researchers try to piece together a therapeutic strategy against the ongoing COVID-19 pandemic, a recent retrospective study from Cleveland Clinic Abu Dhabi, assessed the Hydroxychloroquine's efficacy in increasing SARS-CoV-2 viral clearance, finding that it appeared to significantly slow viral clearance in mild to moderately ill COVID-19 patients.

5 May 2020

A $10 million grant enables expansion of BCG vaccine trial against COVID-19

An A$10 million grant from the Bill & Melinda Gates Foundation will allow the Murdoch Children's Research Institute's clinical trial of the BCG vaccine against COVID-19 to extend to 10,000 healthcare workers across Australia, Spain and The Netherlands.

4 May 2020

Hydroxychloroquine combined with azithromycin and abnormal heart rhythms in COVID-19 patients

A new study shows that the initially lauded combination of drugs against COVID-19 - Hydroxychloroquine and Chloroquine combined with azithromycin, could lead to abnormal and life-threatening heart rhythms. In patients hospitalized with the novel coronavirus infection or SARS CoV-2, this combination can lead to prolonged QT interval as can be detected on ECG.

3 May 2020

New clinical trial to assess whether hypertension drug may reduce COVID-19 severity

Researchers at University of California San Diego School of Medicine have launched a clinical trial to investigate whether a drug approved for treating high blood pressure, heart failure and diabetic kidney disease might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.

30 Apr 2020

Researchers test clinical safety of gene-based treatment for achromatopsia

People with complete color blindness are born unable to distinguish colors. They see less sharply and are highly sensitivity to glare.

30 Apr 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

New clinical trial launched to study if convalescent plasma can treat COVID-19

Montefiore Health System, Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma- taken from people who have recovered from COVID-19-;is effective in treating the disease.

29 Apr 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Testing of hydroxychloroquine for COVID-19 begins at Montefiore And Einstein

Researchers at Montefiore Health System and Albert Einstein College of Medicine have begun testing the drug hydroxychloroquine for the treatment of COVID-19, as part of a nationwide trial sponsored by the National Heart, Lung, and Blood Institute

29 Apr 2020

Arthritis drug assessed as potential treatment for COVID-19-related pneumonia

UC San Diego Health has launched a Phase III clinical trial, part of a global effort, to assess whether a medication used to treat rheumatoid arthritis and other inflammatory disorders might also have therapeutic value for COVID-19 patients who have developed or at high risk of developing serious lung damage from SARS-CoV-2 infections.

29 Apr 2020

Drug reduces risk of men with pedophilic disorder sexually abusing children

A drug that lowers levels of the male hormone testosterone in the body reduces the risk of men with pedophilic disorder sexually abusing children, a study from Karolinska Institutet published today in the journal JAMA Psychiatry shows.

29 Apr 2020

India's Serum Institute gears up to make millions of doses of potential COVID-19 vaccine

The Serum Institute of India plans to start manufacturing Oxford University's COVID-19 vaccine in 3 weeks to get a head start on production, the company announced. This comes even as experts warn that any successful vaccine will take two or more years to come on the market.

28 Apr 2020

The approved dose of ivermectin alone not useful in treating COVID-19

A new paper published on the preprint server medRxiv in April 2020 shows that the use of the already approved drug ivermectin in clinical trials to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)s not feasible. This contradicts earlier reports of its ability to suppress the virus in vitro.

27 Apr 2020

Investigational drug may hold benefit for patients with lung and ovarian cancers

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.

27 Apr 2020